Table 2.
Characteristics of individuals in Scotland and number and rate of severe COVID-19 outcomes 14 days or more after first dose of vaccine
| BNT162b2 vaccination (n=841 090) | Severe COVID-19 outcome among BNT162b2 recipients, n (rate per 1000 person-years) | ChAdOx1 vaccination (n=1 730 918) | Severe COVID-19 outcome among ChAdOx1 recipients, n (rate per 1000 person-years) | ||
|---|---|---|---|---|---|
| Overall | .. | 593 (5·3) | .. | 603 (4·1) | |
| Sex | |||||
| Female | 525 708 (62·5%) | 353 (4·9) | 892 597 (51·6%) | 328 (4·2) | |
| Male | 315 382 (37·5%) | 240 (5·8) | 838 321 (48·4%) | 275 (4·0) | |
| Age, years | |||||
| 18–64 | 476 007 (56·6%) | 107 (1·8) | 1 183 653 (68·4%) | 128 (1·9) | |
| 65–79 | 328 733 (39·1%) | 158 (3·3) | 368 772 (21·3%) | 169 (3·3) | |
| ≥80 | 36 350 (4·3%) | 328 (62·8) | 178 493 (10·3%) | 306 (10·6) | |
| Previous history of COVID-19 | |||||
| No | 807 322 (96·0%) | 562 (5·2) | 1 680 952 (97·1%) | 592 (4·1) | |
| Yes | 33 768 (4·0%) | 31 (7·0) | 49 966 (2·9%) | 11 (3·3) | |
| Previous history of hospitalisation* | |||||
| No | 828 156 (98·5%) | 552 (5·0) | 1 683 125 (97·2%) | 516 (3·6) | |
| Yes | 12 934 (1·5%) | 41 (25·2) | 47 793 (2·8%) | 87 (18·7) | |
| Residential care home | |||||
| No | 822 585 (97·8%) | 336 (3·0) | 1 730 220 (>99·9%) | 600 (4·1) | |
| Yes | 18 505 (2·2%) | 257 (98·3) | 698 (<0·1%) | 3 (37·3) | |
| Deprivation status | |||||
| 1—Most deprived | 155 179 (18·4%) | 142 (6·8) | 313 656 (18·1%) | 186 (7·0) | |
| 2 | 166 798 (19·8%) | 131 (5·8) | 338 012 (19·5%) | 154 (5·3) | |
| 3 | 168 335 (20·0%) | 115 (5·2) | 357 721 (20·7%) | 79 (2·5) | |
| 4 | 178 334 (21·2%) | 105 (4·4) | 359 330 (20·8%) | 90 (3·0) | |
| 5—Least deprived | 167 512 (19·9%) | 88 (3·8) | 353 701 (20·4%) | 93 (3·2) | |
| Unknown | 4932 (0·6%) | 12 (18·8) | 8498 (0·5%) | 1 (1·6) | |
| Urban rural score | |||||
| 1—Large urban area | 250 598 (30·0%) | 160 (4·7) | 525 452 (30·5%) | 205 (4·7) | |
| 2 | 340 101 (40·7%) | 240 (5·2) | 650 895 (37·8%) | 257 (4·7) | |
| 3 | 81 977 (9·8%) | 53 (4·9) | 176 046 (10·2%) | 66 (4·3) | |
| 4 | 42 682 (5·1%) | 33 (6·0) | 96 203 (5·6%) | 99 (2·1) | |
| 5 | 72 339 (8·7%) | 80 (8·3) | 175 879 (10·2%) | 44 (2·9) | |
| 6—Remote rural area | 48 461 (5·8%) | 15 (2·5) | 97 945 (5·7%) | 11 (1·2) | |
| Unknown | 4932 (0·6%) | 12 (18·8) | 8498 (0·5%) | 1 (1·6) | |
| Smoking status | |||||
| Ex-smoker | 139 457 (16·6%) | 139 (7·2) | 293 335 (16·9%) | 173 (5·6) | |
| Non-smoker | 333 702 (39·7%) | 189 (4·2) | 665 821 (38·5%) | 202 (3·6) | |
| Smoker | 194 897 (23·2%) | 129 (4·9) | 426 662 (24·6%) | 172 (4·6) | |
| Unknown | 173 034 (20·6%) | 136 (6·0) | 345 100 (19·9%) | 56 (2·4) | |
| Number of comorbidities† | |||||
| 0 | 420 033 (49·9%) | 82 (1·5) | 813 191 (47·0%) | 95 (1·8) | |
| 1 | 244 230 (29·0%) | 85 (2·6) | 516 013 (29·8%) | 122 (2·7) | |
| 2 | 103 811 (12·3%) | 124 (8·8) | 234 146 (13·5%) | 134 (5·2) | |
| 3 | 42 751 (5·1%) | 124 (20·9) | 98 449 (5·7%) | 112 (8·9) | |
| 4 | 18 212 (2·2%) | 76 (29·8) | 41 944 (2·4%) | 62 (10·7) | |
| ≥5 | 12 053 (1·4%) | 102 (59·9) | 27 175 (1·6%) | 78 (19·9) | |
| Number of previous COVID-19 tests‡ | |||||
| 0 | 612 187 (72·8%) | 151 (1·9) | 1 447 426 (83·6%) | 373 (3·0) | |
| 1 | 114 362 (13·6%) | 87 (5·6) | 198 666 (11·5%) | 95 (6·0) | |
| 2 | 33 236 (4·0%) | 67 (14·7) | 44 994 (2·6%) | 43 (10·4) | |
| 3 | 14 665 (1·7%) | 82 (40·6) | 14 747 (0·9%) | 19 (12·1) | |
| 4–9 | 29 236 (3·5%) | 154 (37·2) | 18 212 (1·1%) | 54 (24·8) | |
| ≥10 | 37 404 (4·4%) | 52 (9·7) | 6873 (0·4%) | 19 (25·8) | |
| Medical history | |||||
| Asthma | 110 799 (13·2%) | 57 (5·3%) | 241 873 (14·0%) | 112 (3·9) | |
| Chronic kidney disease (stages 3–5) | 44 133 (5·2%) | 142 (11·1%) | 107 836 (6·2%) | 176 (22·6) | |
| Liver cirrhosis | 6237 (0·7%) | 4 (7·9%) | 14 064 (0·8%) | 12 (4·7) | |
| Chronic neurological condition | 4567 (0·5%) | 6 (2·3%) | 12 330 (0·7%) | 3 (10·0) | |
| Heart failure | 12 283 (1·5%) | 31 (14·0) | 32 380 (1·9%) | 63 (18·0) | |
| Diabetes (type 1) | 5582 (0·7%) | 4 (2·9) | 14 743 (0·9%) | 4 (5·6) | |
| Diabetes (type 2) | 79 611 (9·5%) | 129 (7·9) | 164 307 (9·5%) | 159 (11·8) | |
| Dementia | 17 274 (2·1%) | 225 (13·2) | 17 278 (1·0%) | 34 (92·6) | |
| Coronary heart disease | 60 379 (7·2%) | 120 (9·0) | 129 636 (7·5%) | 158 (14·2) | |
Data are n (%), unless otherwise indicated. Percentages might not sum to 100 because of rounding.
*
Previous history of hospitalisation status defined as admission to hospital within 4 weeks before first dose of vaccine.
†
Individual QCOVID risk groups found in the appendix (pp 21–22).
‡
A proxy for high-risk occupations.